2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.
Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.
Despite therapeutic advances, surgery has retained its role in the treatment of patients with lung cancer, explains Cerfolio. However, the rate of benign resection has decreased tremendously. Now, the benign resection rate is approximately 5%, whereas it used to range from about 10% to 12%. If anything, surgeons are able to be more selective with surgery because they are now able to more effectively diagnose a patient’s condition in a more minimally invasively way.
However, physicians have just scratched the surface in their understanding of how cancer works, adds Cerfolio. Every day physicians are finding different receptors on cancer cells and other cells and shields. For example, physicians know that PD-L1 protects normal cells and also is on cancer cells. As more research is done, physicians are learning more about how it can get into these cells. With regard to surgery, minimally invasive techniques are going to change practice. It is only a matter of time before surgeons are going to go down through the mouth or the nose to treat lung cancer, concludes Cerfolio.